Biocon
Pfizer terminates $350-mn insulin marketing deal with Biocon
13 Mar 2012
In a surprise move, US drug giant Pfizer Inc, today called off an insulin distribution agreement with Biocon to sell the Bangalore-based company’s biosimilar versions of the drug in key global markets including the US
Biocon to divest stake in Germany's AxiCorp
28 Apr 2011
Biocon Ltd had acquired a controlling stake in the German drug distributor in a bid to market its bio-similar drugs in Europe
.webp)
